ClinicalTrials.gg
TerminatedNCT00690456TOCCATAUpdated May 18, 2016

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Diabetes Mellitus, Type 2, sponsored by Sanofi. Terminated at 13 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-18.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision taken in light of demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing rimonabant in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rimonabant · Diabetes Mellitus, Type 2.

Enrollment
4th of 11
403 · median 358
Started
2008
with 1 other
Phase 3
10 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
10 of 11
Sanofi

Among the 11 studies testing rimonabant in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 10th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 11 studies testing rimonabant in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing rimonabant in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The primary objective of the study is to determine the effect of rimonabant 20 mg daily when added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in patients with type 2 diabetes.

Secondary objectives include evaluation of other markers of glycemic control, lipid profile, body weight, and abdominal obesity. Also, the trial will study the safety of rimonabant when added to metformin over a period of 47 weeks.

Read the detailed description

The total duration per patient will be approximately 49 weeks including a 36-week double-blind treatment period.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Randomized Controlled Trial
  • Metformin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of type 2 diabetes
  • between 7% to 10% at screening visit
  • Treatment with metformin only with a fixed and stable dose of 1500 mg/day or more for at least the past 3 months prior to screening visit

Exclusion criteria

Exclusion Criteria:

  • Within 3 months prior to screening visit: change in lipid modifying agent, administration of systemic for more than 10 days, use of any anti-obesity agent or drugs for weight loss
  • Weight loss of more than 5 kg within 3 months prior to screening
  • Administration of other drugs within 30 days prior to screening visit
  • Prior exposure to type 1 cannabinoid receptor (CB1) antagonists including rimonabant
  • Presence or history of cancer within the past five years
  • Pregnant or breast-feeding women
  • Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Rimonabant

    Rimonabant 20 mg once daily on top of metformin

    Drug: Rimonabant · Drug: Metformin

  • Placebo comparator
    Placebo

    Placebo (for Rimonabant) once daily on top of metformin

    Drug: Placebo (for Rimonabant) · Drug: Metformin

Interventions

  • Tablet, oral administration

    Also known as: SR141716, Acomplia

  • DrugPlacebo (for Rimonabant)

    Tablet, oral administration

  • Metformin continued at stable dose as background therapy

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c

    Time frame: 36 weeks

Secondary outcomes

  1. Change from baseline in fasting plasma glucose

    Time frame: 36 weeks

  2. Change from baseline in body weight

    Time frame: 36 weeks

  3. Percent change from baseline in HDL-C and Triglycerides

    Time frame: 36 weeks

07

Study locations

13 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Jakarta, Indonesia
  • Sanofi-Aventis Administrative Office
    Vilnius, Lithuania
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    México, Mexico
  • Sanofi-Aventis Administrative Office
    Makati City, Philippines
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Bucharest, Romania
  • Sanofi-Aventis Administrative Office
    Moscow, Russia
  • Sanofi-Aventis Administrative Office
    Brastislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Bangkok, Thailand
  • Sanofi-Aventis Administrative Office
    Kiev, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2008
First posted
Jun 4, 2008
Start
May 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Apr 18, 2016
Last update
May 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00690456
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 4, 2008
Start date
May 2008
Primary completion
Feb 2009
Completion
Feb 2009
Last update
May 18, 2016

Study contacts

ICD CSD
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion